Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
Research Report: Stock code:
  25-04-2018 (嚙確)    Jumpcan Pharma (600566.SH) - Pudilan Entered into Shandong PDRL; Robust FY17&18Q1 Results
  24-04-2018 (嚙瘦)    Yutong (600066.CH) - Under New Subsidy Policy, It's Time to Reshuffle and Expand the Industry
  23-04-2018 (嚙瑾)    Yutong (600066.CH) - Under New Subsidy Policy, It's Time to Reshuffle and Expand the Industry
  20-04-2018 (嚙踝蕭)    Tus-sound (000826.SZ) - Impressive Growth and Promising Prospect of Sanitation Business
  19-04-2018 (嚙罵)    Tus-sound (000826.SZ) - Impressive Growth and Promising Prospect of Sanitation Business
[第1頁 / 共649頁]
Jumpcan Pharma(600566)
25-04-18
  Share this article:    
Recommendation on   25-04-18 
Recommendation Accumulate
Price on Recommendation Date $ 47.860
Suggested purchase price N/A
Target Price $ 51.600
Weekly Special - 000538.SZ Yunnan Baiyao
Written by: Eurus Zhou( Research Analyst )
Tel:
+852 2277 6515

Email:
euruszhou@phillip.com.hk

Jumpcan Pharma (600566.SH) - Pudilan Entered into Shandong PDRL; Robust FY17&18Q1 Results

Investment Summary

We highlight that: 1) PAOL and SGYX pill entered into Shandong PDRL; 2) Strong growth in FY17 & 18Q1; 3) Intensifying sales network; 4) Issuing convertible bonds to fund capacity expansion; 5) R&D going well. We assume topline growth in 18E/19E to be 30%/25% and target PE 30x conservatively, thus we get target price of RMB51.6, Accumulate recommendation. (Closing price at 23 Apr 2018)

Business Overview

Pudilan and SGYX pill entered into Shandong PDRL. The company announced on 29 Mar that its exclusive formula Pudilan Anti-inflammatory Oral Liquid (PAOL) and ShenGuiYangXue pills entered into Shandong PDRL, Class II (瞻A类). We expect the sales volume to hike after implementation of PDRL.

Strong FY17 & 18Q1 Results. We see stable growth in 2017: the company achieved revenue of RMB5.64bn (+20.6% YoY), net profit attributable to shareholders of RMB1.22bn (+30.97% YoY) and net profit excluding non-recurring items of RMB1.15bn (+28% YoY). Manufacturing segment turnover reached RMB5.43bn and distribution segment turnover amounted to RMB0.21bn. Selling expenses reported 17.3% YoY growth, roughly in line with topline growth. R&D expenses rose by 34.5% YoY to RMB195mn mainly due to increasing investment in R&D. We also highlight notable growth in 18Q1, which is beyond market expectations: 18Q1 topline was up by 51.45% YoY to RMB2.13bn. GPM remained relatively stable around 84.7% and selling expenses increased by 45%, which generally synchronized with sales growth.

Issuing Convertible Bond to Expand Capacity. In 18Q1, financing costs rose dramatically to RMB3.35mn, attributable to new issuance of RMB828mn convertible bond, which is mainly used to fund capacity expansion (involving the establishment of new buildings, liquid factories, etc.).

Intensifying Distribution Network. The company focuses on three segments, namely Western & Traditional Chinese medicines, TCM daily chemical articles and TCM healthcare products. It continues to enhance distribution channels including hospitals, OTC stores, clinics and supermarkets. With implementation of policies involving tiered medical services and medical union, the company entered more blank regions through intensive academic promotion in primary hospitals. For OTC channel, the company built a strong OTC sales team and enhanced cooperation with other OTC platforms. We see that sales of Iron Proteinsuccinylate Oral Solution (IPOS) and products of newly-acquired subsidiary Dongke continue to climb in 2017.

Progress of Pipeline. During 2017, the company gained production approval of Yangyingqingwei Granules (YYG), clinic trail permissions of three products and six patents. It also launched the construction of Shanghai research center. R&D progress is going well.

Investment Thesis & Valuation

We increase target price to RMB51.6. Given continuously rising sales volume of main products, we estimate that revenue growth to be 30%/25% and EPS to be RMB1.72/2.14 in 18E/19E, with relatively stable margins. We see that currently the average PE of TCM sector is around 28.2x-34.4x. We conservatively assume target PE ratio of 30x to derive 2018 target price of RMB51.6, Accumulate recommendation. (Closing price at 23 Apr 2018)

Risks

Slow than expected expansion of distribution network;

Policy risks;

R&D failure.

Financials

Click Here for PDF format...

Back to Top


Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources believed to be reliable. However, we do not verify such information. We do not guarantee its accuracy or completeness, nor do we take responsibility for any loss occasioned by reliance placed upon the contents hereof. Any statements nonfactual in nature constitute only current opinions, which are subject to change. Phillip Securities (HK) Ltd (or one of its affiliates) or their officers, directors, analysts, or employees may have positions in securities or commodities referred to herein, and may, as principal or agent, buy and sell such securities or commodities. An employee, analyst, officer, or a director of Phillip Securities (HK) Ltd, or its affiliates, may serve as a director for companies mentioned in this report. Neither the information nor opinion expressed in this report shall constitute a solicitation to buy or sell any securities. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. This firm (or one of its affiliates) may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report.
There are risks inherent in international investments, which may make such investments unsuitable for certain clients. These include, for example, economic, political, currency exchange rate fluctuations, and limited availability of information on international securities. We recommend that you obtain the advice of your Financial Advisor regarding this or other investment in order to conform to your financial resources and risk preference

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]